 |
||
)
|
|
|
|
|
|
|
|
|
TLRs |
... | ... | ... | ... |
|
|
CD121a (IL-1RI) + IL-1RAP (membrane-bound and soluble isoforms) [IL-1RAPL1, IL-1RAPL2] |
(100-fold greater avidity for IL-1RI; a 100-fold greater excess of IL-1RA
over IL-1 may be necessary to inhibit biological responses to IL-1) |
|||
| CD121b (IL-1RII) (decoy receptor) |
(100-fold greater avidity for IL-1RI; a 100-fold greater excess of IL-1RA
over IL-1 may benecessary to inhibit biological responses to IL-1) |
||||
| IL-1R-like 1 / T1 / ST2 | Th2 lymphocytes |
IL-1R-like 1 ligand / ST2L |
|||
| IL-1R-like 2 | IL-1 family, member 9 |
||||
|
|
IL-18R (heterodimeric : IL-18R1 / IL1Rrp + IL-18RAP / AcPL (enhances the IL-18 binding activity of IL-18R1)) | IL-1z
IL-18 |
|||
| TRADD | TNFRSF1A / CD120a / p55TNFRI | airway epithelium |
ref |
||
| TRADD | TNFRSF1B / CD120b / p75TNFRII |
|
|||
| TNFRSF3 / LTbR | most cell types, including cells of epithelial and myeloid lineages, but not on T and B lymphocytes |
heterotrimers |
|||
| TNFRSF4 / CD134 / OX40 | T lymphocytes | CD134L / OX40L |
|||
| TNFRSF5 / CD40 (2 isoforms) | B lymphocytes | membrane-bound or soluble CD154 / 40L |
|||
| TNFRSF6 / CD95 / Apo1 / Fas (8 mRNAs => 7 isoforms: those the TM domain may negatively regulate the apoptosis mediated by the full length isoform) | neutrophils,
activated T cells (excepted when RA-treated), cardiomyocytes |
CD178 / FasL |
|||
| TNFRSF6B / DcR3 / TRAIL-R6 (a, b, c, and d isoforms : a, b, and c are related to RAD3/ERCC2, a plasma membrane Ras-related GTPase, while the latter is a decoy receptor) | activated T lymphocytes |
|
|||
| TNFRSF7 / CD27 | CD27L
CD27BP / SIVA |
||||
| TNFRSF8 / CD30 / Ki-1 Ag (2 isoforms) | activated, but not by resting, T and B cells | CD153 / 30L |
|||
| TNFRSF9 / CD137 / 4-1BB | peripheral monocytes, T cells | CD137L / 4-1BBL |
|||
| TNFRSF10A / DR4 / TRAIL-R1 / Apo-2 | transformed cells | TRAIL |
|||
| TNFRSF10B / DR5 / TRAIL-R2 : 2 isoforms | transformed cells |
|
|||
| TNFRSF10C / DcR1 / TRAIL-R3 | many normal tissues but not in most cancer cell lines | TRAIL |
|||
| TNFRSF10D / DcR2 / TRAIL-R4 | ? | TRAIL |
|||
| TNFRSF11A / RANK / TRANCER | osteoclast progenitor cells, T cells | OPG-L / RANK-L / ODF |
|||
| TNFRSF11B
/ OPG (synthesis is up-regulated by 17bE2) |
soluble decoy receptor released from stromal cells/osteoblasts |
|
|||
| TNFRSF12A / FN14 / TWEAKR | TWEAK |
||||
| TNFRSF13B / TACI | B lymphocytes
activated T lymphocytes |
|
|||
| TNFRSF13C / BAFF-R / BR3 | B lymphocytes | membrane-bound or soluble BLys / BAFF / THANK
/ TALL-1 / zTNF4 |
|||
| TNFRSF14 / HVEM / TR2 / LIGHTR | ? |
|
|||
| TNFRSF16 / p75NTR | neurons | NGF
rabies virus glycoprotein (RVG) |
|||
| TNFRSF17 / BCMA | B lymphocytes |
|
|||
| TNFRSF18 / AITR / GITR / GITR-D; 3 isoforms | activated T cells | AITRL / GITRL |
|||
| TNFRSF19 / TAJ / TROY / TRADE / TAJ-alpha ; 2 isoforms | highly expressed during embryonic development | ||||
| TRADD | TNFRSF21 / DR6 / BM-018 | ? | |||
| TNFRSF22 / SOBa / Tnfrh2 / 2810028K06Rik | |||||
| TNFRSF23 / mSOB / Tnfrh1 | |||||
| TNFRSF25 / DR3 / TR3 / DDR3 / LARD / APO-3 / TRAMP / WSL-1 / WSL-LR / TNFRSF12 ; 11 isoforms | expressed preferentially in the tissues enriched in lymphocytes | TL1A |
|||
| EDAR | ectodysplasin A isoform 1 (EDA1) |
||||
| XEDAR | ectodysplasin A isoform 2 (EDA2) |
||||
| CD28 / Tp44 | T lymphocytes |
|
|||
| CD152 / CTLA-4 | cytotoxic T-lymphocyte |
|
Web resources :
Copyright © 2001-2005 Daniele Focosi.
All rights reserved
| Terms of use | Legal
notices
|
|
|
|
|
